loader
Please Wait
Applying Filters...
menu
    • menu

    Annual Sales of Abciximab reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Abciximab

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 2Reopro

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Reopro

    Abciximab

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Reopro

    U.S.A
    arrow
    Discovery on Target
    Not Confirmed

    Eli Lilly

    Abciximab

    Main Therapeutic Indication : Cardiovascular

    Currency : USD

    2015 Revenue in Millions : 111

    2014 Revenue in Millions : 98

    Growth (%) : -12%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Reopro

    Abciximab

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Reopro

    U.S.A
    arrow
    Discovery on Target
    Not Confirmed

    Eli Lilly

    Abciximab

    Main Therapeutic Indication : Cardiovascular Diseases

    Currency : USD

    2016 Revenue in Millions : 87

    2015 Revenue in Millions : 98

    Growth (%) : -11

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF